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Cardiovascular diseases and cancer are the two leading causes of morbidity and mortality worldwide. Improvement in cancer
therapyhasledtoincreasingnumberofcancersurvivors,someofwhommaysuﬀerfromadversecardiovasculareﬀects ofradiation
therapy. Longterm followup is essential, as the cardiac complication may manifest years after completion of radiation therapy. In
this paper, we have discussed the cardiovascular eﬀects of radiation therapy.
1.Introduction
Cardiovascular disease and cancer are the two leading causes
of morbidity and mortality worldwide [1]. Over the last half
century, radiation therapy (RT) has evolved to become one
of the cornerstones of treatment for various types of cancers.
It is estimated that more than 50% of patients with cancer
aretreatedwithradiotherapy.Alongwiththedevelopmentof
novel chemotherapeutic agents, radiation therapy (RT) has
revolutionizedtheprognosisofpatientswithvariouscancers.
Many childhood and adolescent years cancers are now
successfully treated and these patients go on to live an active
and normal adult life, as evidentb ya ni n c r e a s i n gn u m b e ro f
cancersurvivors[2].Latecardiovasculareﬀectsareseenoften
in cancer survivors. Amongst Hodgkin lymphoma (HL)
patients who have received radiation, cardiovascular disease
(CVD) is of the most common causes of death. Studies have
shownthatthesepatientshaveanincreasedriskforCoronary
Artery Disease (CAD), valvular heart disease, congestive
heart failure (CHF), pericardial disease and sudden death.
The risk is particularly high in patients treated before the age
of 40 years [3–6].
The reported relative risk of death from a fatal myocar-
dial infarction in patients treated with mediastinal RT
is increased from 1.5 to 3.0 times that of unirradiated
patients [7, 8]. In young patients undergoing mediastinal
irradiation, myocardial ischemia and CAD is very prevalent
[9]. A meta-analysis of eight randomized trials found a
62% increase in cardiac deaths among women who were
treated with radiation therapy [10]. Even at lower radiation
doses, there appears to be of excess risk of cardiovascular
disease as shown in the Japanese atomic bomb survivors
[11]. Due to improvement in radiation technique, the risk
of cardiovascular complications in relation to radiation may
have declined over time, but even in patients treated as
lately as between 1979 and 1986 the risk congestive heart
failure and valvular dysfunction remained increased [12].
Radiation damage to the heart can involve the pericardium,
myocardium, valves, and coronary vessels with pericardium
being most frequently involved [13, 14]. Radiation damages
the vascular endothelium, and hence radiation-induced vas-
cularinjuryoccursintheﬁeldofradiationexposure.Damage
to the capillary vessels manifests as telangiectasia, whereas
thrombotic, inﬂammatory, and ﬁbrogenic complications in
larger vessels can result in peripheral, coronary and carotid
artery disease. Table 1 lists the possible radiation induced
cardiovascular complications.
Figure 1 illustrates the case of a patient who had multiple
cardiovascularcomplicationsinrelationtoradiationtherapy.
Patient had Hodgkin’s disease and completed radiation
therapy (total of 40Gy) to the mediastinum and neck
in 1984. In 2005, a permanent pacemaker was inserted
for complete heart block. In March 2007, he underwent
pericardiocentesis, followed by a pericardial window. Sub-
sequently he underwent pericardial stripping for pericardial
constriction in April 2007. He also developed CAD and was2 Cardiology Research and Practice
Table 1: Spectrum of radiation induced heart disease.
(1) Radiation-induced atherosclerosis
(a) Symptomatic
(b) Asymptomatic
(2) Pericardial disease
(a) Acute pericarditis
(b) Delayed pericarditis
(c) Pericardial eﬀusion
(d) Constrictive pericarditis
(3) Myocardial and Endocardial disease
(a) Pancarditis
(b) Cardiomyopathy
(4) Valvular disease
(5) Conduction disturbances
(a) RBBB
(b) Atrioventricular nodal block
found to be 50% disease of the left anterior descending
artery. His other radiation-included complications included
hypothyroidism and restrictive lung disease.
2.Possible Mechanism of
Radiation-InducedVascularDisease
The exact primary mechanisms by which radiation-induces
orpromotesatherosclerosishavenotbeenidentiﬁed.Anum-
ber of acute eﬀects, including endothelial damage, lipid and
inﬂammatory cellinﬁltration, and lysosomalactivation, have
been described [15, 16]. Primary basic mechanism behind
radiation induced vascular damage appear to be endothelial
dysfunction [17]. However certain risk factors like smoking
and hyperlipidemia appears to act as accelerating agents.
Radiation itself can cause ﬁbrotic changes in the coronary
arteries [14], butcholesterol feeding of the animals markedly
increased the degree of atherosclerosis in the rabbits [18].
Theseﬁndings suggestthatthecombinedeﬀectofirradiation
and some other risk factor is necessary to producesigniﬁcant
radiation-induced atherosclerosis [18].
Though previously initiation of atherosclerosis was
attributed mainly to lipid accumulation within the arterial
walls, it is now widely accepted that inﬂammation plays a
vital role in the initiation and progression of the disease [19,
20].In animal modelirradiation acceleratesthedevelopment
of macrophage-rich, inﬂammatory atherosclerotic lesions
prone to intraplaque hemorrhage [21] and enhances the
atherogenic eﬀects of a high-fat diet [22]. It is postulated
that radiation promotes short-lived changes in oxidative
stress conditions (O2 concentrations) in the artery wall
and that atherogenic lipoproteins, which are elevated in
response to the high-fat diet, must be available during this
period to participate in the initiation of the disease process
[22]. Another mechanism of radiation-induced endothelial
dysfunction is via production of reactive oxygen species
[23]. Signiﬁcant increases in superoxide and peroxides were
Figure 1: Echocardiogram image (apical 4-chamber view) shows
thickened pericardium, small pericardial eﬀusion, and a pacemaker
lead in the right ventricle.
observed in the microvessels of rats exposed to radiation
[23].
A proposed mechanism of inﬂammatory vascular dam-
age due to radiation in humans is also via oxidative stress
and activation of nuclear factor-kappa B ( NF-kB) [24].
Certain cytokines and growth factors, such as TGF-beta1
and IL-1 beta, may stimulate radiation-induced endothelial
proliferation, ﬁbroblast proliferation, collagen deposition,
and ﬁbrosis leading to advanced lesions of atherosclerosis
[25].
Indirect association of inﬂammation with radiation-
induced vascular damage comes from studies showing
elevated levels of the proinﬂammatory cytokines IL-6, CRP,
TNF-α,a n dI N F - γ and also increased levels of the anti-
inﬂammatory cytokine IL-10, in the Japanese atomic bomb
survivors [26, 27]. There was also dose-related elevation in
erythrocyte sedimentation rate and in levels of IgG, IgA and
totalimmunoglobulinsinthiscohort,allmarkersofsystemic
inﬂammation [27]. In experimental atherosclerosis model
it has been shown that following multiple small radiation
doses the chemoattractant (MCP-1) concentration increases
proportionally to cumulative dose; this increase in MCP-1 is
largely driven by radiation-induced monocyte death [28]. In
an animal model, following a single dose of radiation to the
heart, from 3 months onwards changes in coronary arteries
of the irradiated hearts included endothelial cell loss, a loss
of smooth muscle cells, and ﬁbrosis in media and adventitia
[29].
Endothelial cell injury markers secreted after irradiation
includes thrombomodulin [30]. Following radiation, the
endothelial cell neutrophil chemotactic activity is increased,
with greater adherence of polymorphonuclear leucocytes
to irradiated endothelial cells [31]. In women with breast
cancer, it has been shown that endothelium-dependent
vasodilatation was signiﬁcantly impaired in the irradiated
axillary arteries compared with the contra lateral, nonirra-
diated arteries [32]. In irradiated human cervical arteries,Cardiology Research and Practice 3
the impaired nitric oxide-mediated relaxation was associated
with a lack of endothelial nitric oxide synthase expression,
suggesting the importance of impaired endothelial function
in irradiated human blood vessels [33]. Endothelial cell
swelling, increased permeability, interstitial ﬁbrin deposi-
tion, and development of platelet thrombi ultimately lead
to ﬁbrosis. Various local and systemic factors, implicating
endothelialcell damage and inﬂammation, eventuallylead to
the development of symptomatic CAD.
3.Radiation-InducedCAD
Due to high prevalence of CAD, the precise incidence of
radiation induced accelerated atherosclerosis is diﬃcult to
conﬁrm. However it occurs in a number of patients without
traditional risk factors for CAD [9, 34]. In these patients,
conventional risk factors like CAD, diabetes mellitus, hyper-
lipidemia, and smoking were uncommon and insensitive
indicators of coronary risk after mediastinal irradiation [9].
3.1. Pathology. Intimal proliferation of mainly ﬁbrous tissue
leads to luminal narrowing [14]. Histologically there may be
some overlap and it may be diﬃcult to distinguish between
radiation-induced CAD(RICAD)and typicalatherosclerotic
CAD. However media is more severely destroyed and the
adventitia is markedly thickened and ﬁbrotic in radiation-
induced CAD as compared with nonradiation CAD [35]. In
irradiated coronary vessels, there also appears to be loss of
smooth muscle cells from the media and adventitial ﬁbrosis
[14].
3.2. Clinical Presentation. Symptoms of CAD may include
chest discomfort with or without radiation to the arm,
back, neck, jaw, or epigastrium, shortness of breath, weak-
ness, diaphoresis, nausea, and lightheadedness, all with or
without exertion. Women and the elderly are more likely
to present with “atypical features” [36]. Clinically patients
with radiation induced CAD (RICAD), most commonly,
present with angina, dyspnea or heart failure [34]; however
there are reports of sudden death in patients treated with
radiotherapy [14]. Sudden death in these patients is thought
either to diﬀuse ﬁbrointimal hyperplasia of all coronary
vessels or left main stenosis and ostial lesions [14, 34].
Mean time interval for the development of RICAD in
relation to radiotherapy is approximately 82 months (range
59–104) [13]. Patients with RICAD generally present at
younger age than general population, especially survivor
of childhood and adolescence malignancies treated with
mediastinal radiation [37]. Hancock et al. followed a total
of 2232 consecutive Hodgkin’s disease patients treated from
1960 through 1991 for an average of 9.5 years to assess
the risk of death from heart disease after Hodgkin’s disease
therapy. The relative risk (RR) for cardiac death was found
to be 3.1 (CI; 2.4–3.7) and the RR for acute myocardial
infarction was the highest after irradiation before 20 years
of age and decreased with increasing age at treatment (P<
.0001 for trend) [8]. The proximal coronary vessels, which
are in the range of radiation, are mainly involved [13, 14].
Occasionally in patient with myocardial infarction due
to previous radiation therapy, no obstructive CAD is found
and provocative tests for coronary artery spasm response are
normal [38]. Spontaneous recanalization of the thrombus
m a yh a v eo c c u r r e da st h i sp a t i e n tw a st r e a t e dw i t ha s p i r i n
and heparin and coronary angiogram was done 3 days later
[38].
Asymptomatic disease is also prevalent in patients with
previous radiation. New perfusion defects occurred in 50%
to 63% of women 6 to 24 months after RT [39, 40]. Marks
et al. demonstrate 27%, 29%, 38%, and 42% incidence
of myocardial perfusion abnormalities in asymptomatic
patients with breast cancer at 6, 12, 18, and 24months after
RT, respectively [41]. The incidence of perfusion defects
was strongly correlated with the volume of left ventricle
(LV) in the RT ﬁeld occurring in 25% of patients with 1%
to 5% of the LV within the tangent ﬁelds, and in 55%
of patients with more than 5% of the LV within the ﬁeld
[41]. The clinical signiﬁcance of these perfusion defects
is unknown. However, they appear to be associated with
abnormalities in wall motion and episodes of chest pain
[41, 42]. A nonsigniﬁcant change in ejection fraction is
apparent only in patients with relatively large fractions of the
LV aﬀected by perfusion defects [41]. In patients with distal
esophageal cancer, RT is associated with a high prevalence
of inferior left ventricular ischemia, as detected by gated
myocardial perfusion images (GMPIs) [43]. Most perfusion
defects are encompassed within an isodose line ≥45Gy in
t h eR Tp l a n ,a n dm o s tp a t i e n t sh a v em i l dd e g r e eo fi s c h e m i a
[43]. A wall motion abnormality was seen in only few
patients; such ﬁnding is likely due to the presence of only
mild degree of ischemia [43]. In a small group of patients
with esophageal and lung carcinoma, myocardial perfusion
abnormalities were frequently seen after radiation but were
not predictive of future cardiac events [44]. Due to small
number of patients in these series and short duration of
followup [41, 42, 44], the long-term clinical signiﬁcance of
these mild perfusion defects is unknown.
3.3. Diagnosis and Treatment. Diagnosis and treatment of
radiation-induced CAD (RICAD) is similar to CAD in
general population [45]. There are no speciﬁc guidelines or
signiﬁcant diﬀerence in the acute initial stabilization and
management of these patients. Generally the treatment of
both acute and chronic RICAD would follow the same lines
as management of atherosclerotic CAD either with medical
therapy or revascularization, considering the patient’s symp-
toms, cancer stage, expected survival, and comorbidities.
For patients with RICAD, both percutaneous inter-
vention and coronary artery bypass graft (CABG) have
been used [34]. Surgical intervention and CABG may pose
diﬃculties in these patients because of mediastinal ﬁbrosis,
with high incidence of complications [34]. In addition, the
use of internal mammary artery as a graft may not always be
possible due to radiation disease with this vessel itself.
Figure 2 represents a CT coronary angiogram showing
left main disease in a 60-year-old female who had received
radiation therapy to the mediastinum.4 Cardiology Research and Practice
Figure 2: CT coronary angiogram showing left main disease
in a 60-year-old female who had received radiation therapy the
mediastinum.
4.Radiation-InducedCarotidArteryDisease
In patients with Hodgkin’s disease, when compared to
controls, the irradiated cases had a greater intima-media
thickness in the carotid artery distribution [46]. During
a 3-year followup, it was noted that despite improvement
in intima-media thickens at 3 years, there was persistently
reduced ﬂow-mediated dilatation in the irradiated carotid
artery, suggesting thatearly endothelialdamage persists [47].
Radiation-induced carotid disease diﬀers from traditional
carotid disease. Radiotherapy often produces carotid lesions
that are more extensive than the traditional bifurcation
stenosis, often involving atypical areas such as long segments
of carotid artery [48].
The treatment of radiation-induced carotid disease is
similar to those in general population with both percuta-
neous intervention and surgery used in selective cases [49].
In patients with extensive ﬁbrosis due to radiation,
carotid stenting may be preferable.
Figure 3 represents a carotid Doppler of a 33-year-old
female who had received head and neck radiation for
nasopharyngeal carcinoma 18 yrs ago, showing moderate
disease in the left common carotid artery. The patient also
had evidence of occlusion of the left subclavian artery.
5.Radiation-InducedPericardialDisease
Pericardial disease is a common manifestation of radiation-
induced heart disease and is most frequently involved. In an
autopsy study of radiation-induced heart disease, radiation-
induced pericardial disease was noted in 70% of cases in
whom pericardium was available [13].
5.1. Pathophysiology. Fibrosis is a common sequel of radio-
therapy. It is a multicellular process involving various
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Figure 3: A carotid Doppler shows moderate disease in the left
common carotid artery of a 33-year-old female who had received
head and neck radiation for nasopharyngeal carcinoma 18years
ago.
interacting cell systems in the heart resulting in the ﬁbrotic
phenotype of the ﬁbroblast/ﬁbrocyte cell system, which
usually causes ﬁbrous thickening of the pericardium [50].
In the pericardium, parietal surfaces are more severely
damaged, with dense collagen and ﬁbrin deposition on the
mesothelial surfaces [51].
5.2. Clinical Presentation, Diagnosis, and Treatment. Pericar-
dial disease with radiotherapy can present as pericarditis,
pericardial eﬀusion with or without constrictive pericarditis
[13]. Pericardial eﬀusion with or without constriction is the
most commonly observed type of pericardial disease [13].
In patients with radiation-induced pericardial disease,
theintervalfromradiationtherapytosymptomdevelopment
is variable and ranges between 2 and 145 months (mean
time:58months)[13].Patientspresentingearliest were those
with eﬀusions, whereas those with constriction all became
symptomatic after 18 months [13]. The development of
disease 12 years after treatment emphasizes the importance
of long-term followup in these patients [13].
Pericardial disease with radiotherapy can present as the
following cases.
(1) Acute pericarditis during radiation treatment: the
signs and symptoms are those of nonspeciﬁc peri-
carditis with chest pain, fever, and sometimes
nonspeciﬁc ECG abnormalities. (Figure 4 repre-
sents an ECG showing pericarditis in a 60-year-
old female who presented with chest pain 7 days
after starting radiationtherapyforbreastcarcinoma).
Acute pericarditis during radiation treatment gen-
erally responds to bed rest and nonsteroidal anti-
inﬂammatory drugs (NSAIDs). Treatment of pri-
mary malignancy should not be withheld because of
this.
(2) Delayedpericardialdisease:itcanoccurfrommonths
to several years after radiotherapy [52, 53]. PatientsCardiology Research and Practice 5
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Figure 4: ECG showing ST elevation suggestive of pericarditis.
may present with pericardial pain, but dyspnea is the
commonest presenting symptom [52, 53].
Delayed chronic pericardial eﬀusion: it may present
within 4–26 months and is usually detected by
chest X ray showing an enlarging cardiac silhouette
[52]. Radiographic evidence of cardiomegaly usually
precedes the development of dyspnea and other
signs of tamponade [52]. Some patients may present
with tamponade. When delayed pericardial disease
presents with a cardiac tamponade like clinical
picture,needle pericardiocentesis isusually the initial
treatment of choice. Recurrent, large, and hemo-
dynamically signiﬁcant pericardial eﬀusions require
surgical pericardiectomy, if no contraindications
exist [52].
(3) Pancarditis: the most severe form of radiation-
inducedpericardial disease is pancarditis. In addition
to pericardial ﬁbrosis, there is myocardial ﬁbrosis
with or without endocardial ﬁbrosis or ﬁbroelas-
tosis. Clinical picture is that of intractable conges-
tive heart failure. When radiation-induced pancar-
d i t i sp r e s e n t sa sa c u t ed e c o m p e n s a t e dh e a r tf a i l -
ure, besides early risk stratiﬁcation, patients should
be treated with loop diuretics, nitroglycerin, ACE
inhibitors, vasodilators, inotropic agents, and sup-
portive device as indicated.
(4) Constrictive Pericarditis: mediastinal radiation is a
common cause of constrictive Pericarditis [54]. The
majority of the patients present many years after
radiation therapy with congestive heart failure [54].
Congestive heart failure is treated with conventional
medications like diuretics, beta blockers and ACE
inhibitors. The deﬁnite treatment is pericardiectomy,
butradiation therapy is associated with poor survival
in these patients, and hence pericardiectomy may
not be curative for patients with radiation-induced
constrictive pericarditis [54].
(5) In clinical practice some asymptomatic patients may
have minimal to small pericardial eﬀus i ononr outi n e
echocardiogram. Exceptforfollowup,noactiveinter-
vention is needed in these cases.
6.Radiation-InducedCardiomyopathy
A large number of patients with previous radiation therapy
develop cardiomyopathy. In a retrospective cohort study
involving 14,358 ﬁve-year survivors of various cancers
diagnosed and treated under the age of 21 between 1970 and
1986, Mulrooney et al. found that survivors of cancer were
signiﬁcantly more likely than siblings to report congestive
heart failure (hazard ratio (HR) 5.9, 95% conﬁdence interval
3.4 to 9.6; P<. 001). Exposure to 250mg/m2 or more of
anthracyclines and radiation dose of more than 1200cGy
to the heart increased the relative hazard of congestive
heart failure by two to sixfold as compared to nonirradiated
survivors [55].
Overall, heart failure is a rare sequel of mediastinal
radiation therapy and mostly associated with a restrictive
hemodynamic pattern in the absence of a history of treat-
ment with an anthracycline [56]. At a microscopic level
collagen not only increases as a whole but the proportion
of type I collagen increases proportionally to type 111. This
marked alteration in collagen synthesis may contribute to
impaired diastolic distensibility of the ventricles seen in
this group of patients [57]. Most patients with myocardial
involvementhaveinterstitialﬁbrosis[13].Themostcommon
pattern of ﬁbrosis is pericellular and perivascular, with
replacement ﬁbrosis seen infrequently [13]. The loss of
myocardium results inrenin-angiotensin-aldosterone (RAA)
and adrenergic system-driven myocardial remodeling, which
is progressive and results in end-stage symptoms.6 Cardiology Research and Practice
Multiple case series have reported myocardial perfusion
defects in patients receiving mediastinal radiation therapy
[39, 58–60]. The signiﬁcance of these perfusion defects
is unclear. However, they likely represent microvascular
damage to the myocardium, which over time may lead
to myocardial ﬁbrosis and diastolic dysfunction [61]. Even
if acute myocardial damage is only moderate, the pro-
cess of myocardial remodeling can lead to progressive
myocardial dysfunction over years and eventually induce
myocardial dysfunction and heart failure. Treatment with
ACE inhibitors, angiotensin receptor blockers, aldosterone
antagonists, and beta blockers is usually recommended as
per guidelines for treatment of heart failure in general popu-
lation [62]. In animal model, captopril (an ACE inhibitor)
ameliorated many of the structural changes but failed to
inﬂuence or prevent the late functional deterioration after
irradiation of the heart [63].
7.Radiation-InducedValvularHeartDisease
Valvular disease is frequently seen in patients with radiation-
induced heart disease. In one postmortem series, the inci-
dence was high with 81% of patients showing evidence
of valvular damage [14]. The aortic and mitral valves are
more commonly involved than the tricuspid and pulmonary
valves [14, 64]. The reason for preponderance of left-sided
lesion and the rarity of pulmonary valve involvement despite
its anterior position is not known. This may be related to
higher pressure across left-side valves. Only a minority of
patients with radiation-associated valvular disease (RAVD)
have clinically moderate or severe dysfunction [14]. Vast
majority (71%) of patients with RAVD exhibit no symptoms
of valvular dysfunction [65]. The mean time from radiation
to the onset of symptoms in RAVD is approximately 98
months (range 18–252) [13]. In an individual patient
exposed to radiation, it is diﬃcult to assess the time period
for conversion of asymptomatic to symptomatic valvular
heart disease, as radiation-associated valvular heart disease
represents a continuum progressing from asymptomatic
valvular thickening to symptomatic valvular dysfunction.
However, it has been noted that diagnosis of asymptomatic
RAVDoccurredatameanof11.5yearsafterirradiationcom-
pared with 16.5 years for symptomatic patients [65]. Thus, 5
years appear to be the interval required for progression from
asymptomatic to symptomatic RAVD.
The valve leaﬂets are ﬁbrotic with focal dystrophic
calciﬁcation and marked thickening. In the pathological
ﬁndings, certain rheumatic endocarditis changes such as
endocardial reduplication and vascularization are not found
[64].The cuspsorleaﬂetsofthevalvesthickenﬁbrose andon
occasion partially calcify [66, 67]. The treatment of valvular
disease in cancer patientsand those related to radiotherapy is
the same as in general population. The issue of endocarditis
prophylaxis should be individualized.
Figure 5representsDopplerechocardiogramoftheaortic
valve in a 46-year-female showing moderate aortic stenosis
and aortic regurgitation. The patient had received radiation
therapy for Hodgkin’s disease 29 years ago. Some degree of
regurgitation was noted in all 4 valves.
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Figure 5: Doppler echocardiogram of the aortic valve (done in
2005) shows moderate aortic stenosis and aortic regurgitation in a
46-year-female who had received radiation therapy for Hodgkin’s
disease in 1976. Some degree of regurgitation was noted in all 4
valves.
8.Radiation-InducedConduction
System Disease
The conduction system is the least commonly involved of all
the cardiac structures and its true incidence is not known.
ECG changes after irradiation range from nonspeciﬁc ST-
T changes to low voltage and right bundle branch block
(RBBB) [14]. RBBB is commonly associated with medi-
astinal irradiation because the right bundle lies close to
the endocardium on the right side [68]. Injury to bundle
may occur either directly from radiation or indirectly from
associated myocardial ﬁbrosis and ischemia. One of the
common serious manifestations is complete atrioventricular
(AV) block [69]. Dual chamber pacing has been found to
be somewhat more eﬃcacious in symptom improvement
in such patients [70]. A postmortem study in a 20-year-
old man with Hodgkin’s disease and previous radiation
who had earlier developed heart block revealed marked
arteriosclerosis with ﬁbrosis of theepicardium,myocardium,
and endocardium. Examination of the conduction system
revealed extensive arteriolosclerosis of the sinoatrial node
and its approaches. In addition, there was marked ﬁbrosis
of the approaches to the AV node, the AV bundle, and
both bundle branches [71]. Complete heart block has been
reported to occur at an interval of less than 1 year from
radiation to 23 years after completion of radiation therapy
[72]. Hence these patients should be followed up for life.
9.Roleof Biomarkersin
Patients Undergoing Radiation Therapy
There are only few studies of biomarkers in patients under-
going radiation and have shown conﬂicting results. In a
study of 50 women with breast cancer, no change in serum
troponin was found after a total dose of 45 to 46Gy [73].
In this study, however, the cardiac dosimetric data was not
provided [73]. In another study of 30 patients receivingCardiology Research and Practice 7
thoracic chemoradiation, no signiﬁcant elevation in creatine
kinase-myocardial band (CK-MB), troponin, or NT-pro
BNP was detected with radiation therapy [74]. In one study
both troponin and BNP increased signiﬁcantly during the
study; however, the absolute and mean values remained on
a relatively low level (mean preradiation and postradiation
troponinI:0.007±0.008,0.014±0.01ng/mL;meanpreradi-
ation and post radiation BNP:123±147, 159±184pg/mL)
[75]. Hencebased on current knowledge, cardiac biomarkers
are not recommended for evaluation of radiation-induced
cardiotoxicity but remain a useful research tool.
10.Preventionand FutureDirection
Subclinical cardiac damage occurs in >50% of breast cancer
survivors treated with radiation therapy [39]. Alteration
in radiotherapy ﬁeld or targeted radiation, with avoidance
and/or shielding of the heart, remains one of the most
important things in prevention of radiation-induced cardiac
damage. In the absence of risk factors, the value of primary
andsecondary preventioninthesecasesisdebatable.Patients
with classical risk factors like hypertension, smoking, and
hyperlipidemia may be at increased risk of radiation-related
cardiovascular complications, and these risk factors should
be treated aggressively. Younger patients should be screened,
because this patient population at risk usually have a
considerable life expectancy. The role of routine stress test
and biomarkers like troponin and B-type natriuretic peptide
(BNP) in identifying high risk patients or predicting future
cardiovascular events remains to be determined in large
studies.
Similarly, in the absence of risk factors, the role of
prevention therapy like use of antiplatelets, ACE inhibitors,
and lipid lowering agents remains unclear. Recently CT scan
of the coronary artery has been identiﬁed as a useful tool in
identifying RICAD in asymptomatic patients [76]. Studies
of myocardial perfusion in patients with previous radiation
therapy indicate that the majority have mild myocardial
perfusiondefects.Inpatientswithgoodlong-termprognosis,
the ﬁnding of the ischemia due to the RT may be signiﬁcant
as this is a reversible and treatable stage of RICAD, and
halting its progression may decrease the incidence of future
cardiovascular events.
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